KLOW side effects and results in studies
No study has recorded side effects for KLOW itself, because no study has tested the blend. For the components, small human reports of BPC-157 stated no adverse events, the single human GHK-Cu trial did not report adverse events in its abstract, and the KPV and TB-500 records are animal and cell work.
What are the benefits of the KLOW peptide? No study has measured any benefit of KLOW, because no published study has tested GHK-Cu, BPC-157, TB-500 and KPV together. What exists is a separate literature for each component, and the results below are the results of those single-compound studies, grouped by the peptide that was tested.
GHK-Cu: in the one controlled human trial, 13 patients used skin care products with or without GHK-Cu after CO2 laser resurfacing. Blinded evaluators and computer analysis found no significant difference between groups in redness, wrinkles or skin quality at 12 weeks, although patient-rated improvement was higher with GHK-Cu (P = .04). In smoke-exposed mice, GHK-Cu at 0.2 and 2 mg/kg reduced muscle loss and improved grip strength.
BPC-157: in a chart review of 16 people with knee pain, 14 reported relief after intra-articular injection, 12 of them given BPC-157 alone and 4 given BPC-157 with thymosin beta-4. There was no control group and no formal outcome measure. In a 12-woman bladder pilot, 10 reported complete resolution of interstitial cystitis symptoms. In rats with spinal cord compression, one injection improved tail motor function.
TB-500: the records study thymosin beta-4 rather than a product sold as TB-500. In mice, Tβ4 supplementation reversed a worsened allergic asthma phenotype, and systemic Tβ4 changed markers of cardiac remodelling after coronary ligation. Other records link the body's own Tβ4 to gut barrier disruption under stress and to breast cancer cell growth.
KPV: in mice, oral KPV reduced the incidence of chemically induced colitis, and KPV-treated mice regained body weight sooner with lower colonic MPO activity. In mice lacking a working MC1 receptor, KPV rescued all treated animals from death during DSS colitis.
Adverse-event reporting across these records is thin. The BPC-157 pilots in 12 and 2 people reported no adverse events or side effects, the GHK-Cu skin trial abstract does not mention them, and the KPV and TB-500 work gives no human safety data. None of these is a safety study, and none tells you what happens when the four are given together.
Adverse events reported
| Event | As reported | Source |
|---|---|---|
| Adverse events, KLOW blend | Not studied; no published study has tested the four peptides together | |
| Adverse events, BPC-157 bladder pilot (n=12) | No adverse events reported; no dropouts | PMID 39325560 |
| Side effects, BPC-157 intravenous pilot (n=2) | No side effects reported; no measurable effect on tested biomarkers | PMID 40131143 |
| Adverse events, GHK-Cu topical trial (n=13) | Not stated in the abstract | Miller TR et al. |
| Systemic toxicity, GHK-Cu in silicosis mice | No significant systemic toxicity reported | PMID 38879894 |
| Gut barrier, thymosin beta-4 in mice | Tβ4 treatment reduced tight junction proteins; mast-cell Tβ4 disrupted the intestinal barrier under stress | PMID 41278163 |
| Toxicity to intestinal cells, KPV nanoparticles | HA-KPV nanoparticles appeared nontoxic and biocompatible with intestinal cells | PMID 28143741 |
Outcomes measured
| Outcome | Result as reported | Source |
|---|---|---|
| Objective skin measures after laser resurfacing, human (GHK-Cu) | No significant difference between groups at 12 weeks | Miller TR et al. |
| Patient-rated skin quality, human (GHK-Cu) | Higher with GHK-Cu (P = .04) | Miller TR et al. |
| Grip strength, smoke-exposed mice (GHK-Cu) | 175.5 g untreated vs 257.6 g (0.2 mg/kg) and 339.1 g (2 mg/kg) | Deng M et al. |
| Knee pain relief by phone survey, human (BPC-157 alone or with Tβ4, n=16) | 14 of 16 reported relief | Lee E et al. |
| Tail motor function after spinal cord injury, rat (BPC-157) | Improved; spasticity resolved by day 15 | Perovic D et al. |
| Allergic asthma phenotype, mouse (Tβ4) | Worsened phenotype reversed by Tβ4 supplementation | Li Y et al. |
| Cardiac remodelling markers after coronary ligation, mouse (Tβ4) | miR139-5p raised and ROCK1 modulated | Maar K et al. |
| Colitis incidence, mouse (oral KPV) | Reduced for DSS- and TNBS-induced colitis | Dalmasso G et al. |
| Survival, MC1R-deficient mice with DSS colitis (KPV) | All KPV-treated animals rescued from death | Kannengiesser K et al. |
What the studies don't show
There are no data on KLOW as a blend, so any benefit or side effect of the combination is unknown. The human records are small and uncontrolled apart from one 13-patient topical trial, and the rest are animal and cell studies that cannot be read as effects in people.